A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder
about
Levomilnacipran for the treatment of major depressive disorder: a reviewDisclosing the potential impact of placebo controls in antidepressant trials.Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trialsEfficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trialsDisposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humansLevomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III studyA Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.Levomilnacipran: a newly approved drug for treatment of major depressive disorder.Cardiovascular adverse effects of newer antidepressants.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633).Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia.Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder.The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.Efficacy of levomilnacipran extended release in treating major depressive disorder.The Black Book of Psychotropic Dosing and Monitoring.Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable Paliperidone.
P2860
Q28083216-837AB9F7-E001-4124-AD06-FF9E055844CBQ30489955-96489304-310F-41FA-A1B7-B1433DF3074EQ33718213-30D60937-E5E3-4D01-B80A-66642F331948Q35544278-B625E107-0C4A-43B0-8CF8-47CC6B14C1E3Q35794456-92E71638-F044-4A9B-9EB3-28DDC02C38C1Q35799145-6C5CA12D-39A1-43CC-96B3-65C810090451Q36083249-198D870A-CA5D-4104-A881-F0779FF70FA7Q36530043-7852D4C3-E21C-4AAC-9FC1-3912363BFEBFQ36781720-D1C65381-4DB6-4690-BEFE-71FA13238CECQ37077152-2643E985-AA20-4621-B923-9B3F2CE61E8BQ37309556-2F6F7750-7D71-4754-AEAF-AC4F0D876DABQ37404814-2CE3671D-8D2F-458E-8511-9F76ECF3753CQ37605360-778A3047-D454-44FF-873F-CFFAA424B113Q37651165-080AD45B-33B2-48DB-B542-21080BD0EA69Q37694366-A5C15301-25A7-42D2-B968-681EF6B2C05AQ38187697-0F0E12C0-CFC0-44E6-917F-E740977F253DQ38205025-828C2BCC-AF77-47AA-94AA-09E3657EBA28Q38249999-220866DB-860C-4443-A46B-2E0E4556D49DQ38714376-FCCAFB02-B134-4E22-9834-112300740820Q38770060-19158DE0-4929-4A87-80C7-8C28570EE20DQ38786561-8268071D-D39F-4DC4-8836-2713FA2F7C06Q39207094-B75CF973-C448-429F-82DF-58F94354067CQ39689730-DF30387D-5311-49DA-AEF6-7643A8C61C7DQ47141387-8EC389F3-D3FE-4AC9-8722-49A47A1A39BDQ47303967-CE0A48BC-71F4-49FA-BAA0-64540F379849Q47642128-465C9C76-D9C2-4D75-B742-5CC8709BFCC7Q47882128-8A7FAC8F-6DC9-4ACA-9788-FB5CAE3E71B9Q50571111-29896419-ED05-48BA-A89C-A4046C70AFF2Q50708105-DBC9A934-88DB-4BE9-81DB-BBD068E03992
P2860
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A phase III, double-blind, pla ...... with major depressive disorder
@ast
A phase III, double-blind, pla ...... with major depressive disorder
@en
A phase III, double-blind, pla ...... with major depressive disorder
@nl
type
label
A phase III, double-blind, pla ...... with major depressive disorder
@ast
A phase III, double-blind, pla ...... with major depressive disorder
@en
A phase III, double-blind, pla ...... with major depressive disorder
@nl
prefLabel
A phase III, double-blind, pla ...... with major depressive disorder
@ast
A phase III, double-blind, pla ...... with major depressive disorder
@en
A phase III, double-blind, pla ...... with major depressive disorder
@nl
P2093
P2860
P3181
P1476
A phase III, double-blind, pla ...... with major depressive disorder
@en
P2093
Angelo Sambunaris
Anjana Bose
Carl P Gommoll
Changzheng Chen
William M Greenberg
P2860
P3181
P356
10.1097/JCP.0000000000000060
P407
P577
2014-02-01T00:00:00Z